Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of$ 1.27. This compares to loss of $1.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 1.02 per share when it actually produced a loss of $1.31, delivering a surprise of -28.43%.Over the last four quarters, the comp ...